



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/647,678

In re Application of  
Byk et al.

Examiner: ALVARADAO

Art Unit:


Serial No.: 09/647,678

Filed: October 2, 2000

Title: NEW AGENTS FOR TRANSFERRING  
NUCLEIC ACIDS, COMPOSITIONS  
CONTAINING THEM AND THEIR  
USESI hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Commissioner  
for Patents, Washington, D.C. 20231, on

14 August 2001

Date of Deposit



Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)


Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626

Docket No. ST98009A